Obesity drug developer Metsera said on Friday that it accepted Pfizer's $10 billion acquisition offer, in what could be the end of a bidding war between
November 08, 2025
Pfizer plans to sweeten its bid for Metsera, a person familiar with the matter told Reuters, after a judge denied its request to block rival drugmaker Novo
November 05, 2025
Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera
November 04, 2025
The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them
November 04, 2025
WILMINGTON, Del.
November 04, 2025
Novo Nordisk and Pfizer have revised their bids for Metsera, the obesity drug developer said on
November 04, 2025
Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday, as both companies submitted sweetened bids, with
November 04, 2025
By Mike Dolan -What matters in U.S. and global markets today By Mike Dolan, Editor-At-Large, Finance and Markets With one eye on Tuesday's U.S. local elections, stocks have been knocked back sharply
November 04, 2025
Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S.
November 04, 2025
Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.
November 03, 2025
Metsera has become the obesity drug market's hottest ticket.
October 30, 2025
Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in
October 30, 2025
Swiss drugmaker Novartis is exploring options to add more medicines to its direct-to-patient platform that is expected to launch in the U.S. on November 1, CEO Vas
October 28, 2025
White House announces IVF drug pricing deal for ‘TrumpRx’ site
October 16, 2025
Pfizer Chief Executive Albert Bourla said on Tuesday that the U.S. pharmaceutical industry needs to collaborate with China’s, where speedy processes have vaulted
October 15, 2025
Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with
October 10, 2025
European and U.S. healthcare stocks surged on Wednesday, propelled by a deal between Pfizer and President Donald Trump to
October 01, 2025
U.S.
October 01, 2025
Swiss drugmakers could strike their own deals with the U.S. after President Donald Trump's push to lower prescription drug prices led to an
October 01, 2025
Pfizer and President Donald Trump on Tuesday said they had cut a deal in which the U.S.-based drugmaker agreed to lower prescription drug
September 30, 2025
Drugmaker Pfizer has agreed to lower drug costs under a deal struck with President Donald Trump's administration
September 30, 2025
Trump announces ‘TrumpRx’ site for discounted drugs and deal with Pfizer to lower prices
September 30, 2025
U.S.
September 30, 2025
Pfizer announced last month that it will acquire Metsera, a clinical-stage biotech focused on treatments for obesity and cardiometabolic diseases, in a deal valued at an initial $4.9 billion, with the potential to rise to $7.3 billion contingent on achievement of clinical and regulatory milestones. Pfizer will pay $47.50 in cash per Metsera share at closing, reflecting a premium of more than 42% over Metsera’s closing price before the announcement. Metsera shareholders may also receive up to $22.50 additional per share tied to three specified milestones: $5 per share if a Phase 3 trial of the MET-097i + MET-233i combination
September 30, 2025
Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness